Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may off...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Baishideng Publishing Group Inc
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016370/ |
| id |
pubmed-5016370 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-50163702016-09-27 Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease Si, Xiao-Ying Merlin, Didier Xiao, Bo Review Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment. Baishideng Publishing Group Inc 2016-09-14 2016-09-14 /pmc/articles/PMC5016370/ /pubmed/27678353 http://dx.doi.org/10.3748/wjg.v22.i34.7718 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Si, Xiao-Ying Merlin, Didier Xiao, Bo |
| spellingShingle |
Si, Xiao-Ying Merlin, Didier Xiao, Bo Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| author_facet |
Si, Xiao-Ying Merlin, Didier Xiao, Bo |
| author_sort |
Si, Xiao-Ying |
| title |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| title_short |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| title_full |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| title_fullStr |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| title_full_unstemmed |
Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| title_sort |
recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease |
| description |
Inflammatory bowel disease (IBD) is a chronic relapsing disease in gastrointestinal tract. Conventional medications lack the efficacy to offer complete remission in IBD therapy, and usually associate with serious side effects. Recent studies indicated that nanoparticle-based nanotherapeutics may offer precise and safe alternative to conventional medications via enhanced targeting, sustained drug release, and decreased adverse effects. Here, we reviewed orally cell-specific nanotherapeutics developed in recent years. In addition, the various obstacles for oral drug delivery are also reviewed in this manuscript. Orally administrated cell-specific nanotherapeutics is expected to become a novel therapeutic approach for IBD treatment. |
| publisher |
Baishideng Publishing Group Inc |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016370/ |
| _version_ |
1613646732637241344 |